Remedium Lifecare Ltd
Incorporated in 1988, Remedium Lifecare Ltd is in the business of trading in Advanced Pharmaceutical Intermediates and other pharma products
- Market Cap ₹ 141 Cr.
- Current Price ₹ 1.57
- High / Low ₹ 63.4 / 1.57
- Stock P/E 66.0
- Book Value ₹ 0.49
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 3.20 times its book value
- Company has low interest coverage ratio.
- Promoter holding is low: 1.11%
- Earnings include an other income of Rs.10.8 Cr.
- Company has high debtors of 695 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 405 | |
| 406 | |
| Operating Profit | -1 |
| OPM % | -0% |
| 11 | |
| Interest | 5 |
| Depreciation | 0 |
| Profit before tax | 4 |
| Tax % | 51% |
| 2 | |
| EPS in Rs | 0.02 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 22% |
| 3 Years: | -24% |
| 1 Year: | -97% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Equity Capital | 40 |
| Reserves | 4 |
| 1,141 | |
| 535 | |
| Total Liabilities | 1,720 |
| 0 | |
| CWIP | 0 |
| Investments | 0 |
| 1,720 | |
| Total Assets | 1,720 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 695 |
| Inventory Days | 247 |
| Days Payable | 459 |
| Cash Conversion Cycle | 483 |
| Working Capital Days | 1,066 |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Of Newspaper publication as per Regulation 92 of the SEBI(ICDR) Regulations, 2018 and Regulation 30 read with Schedule lll of SEBI(LODR) Regulations, 2015
- The Audited Financial Results (Standalone And Consolidated) Of The Company For The Last Quarter And Year Ended March 31, 2025 And Audited Annual Accounts Of The Company For The Quarter And Year Ended 31St March, 2025 30 May
-
Board Meeting Outcome for The Audited Financial Results (Standalone And Consolidated) Of The Company For The Last Quarter And Year Ended March 31, 2025 And Audited Annual Accounts Of The Company The Quarter And Year Ended 31St March, 2025
30 May - Audited FY25 results approved; two independent directors and new company secretary appointed.
-
Appointment of Company Secretary and Compliance Officer
30 May - Audited FY25 results approved; two independent directors and new company secretary appointed.
-
Announcement under Regulation 30 (LODR)-Change in Management
30 May - Audited FY25 results approved; appointed secretarial auditor, two independent directors, and new company secretary.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1]
Company does trading and sale of API intermediates (KSMs & CRMs) and various other raw materials used in API trading to innovator and generic pharmaceutical players in Domestic and International markets